Arguably, systemic XO inhibition lowers serum UA levels and thus reduces the risk of urate crystal tissue deposition and acute gout flares, an effect that underpins the clinical efficacy of febuxostat (Becker et al., 2009). The gene discussed is XDH; the disease is gout.